LAMA/LABA Combination, Inhalers

• Inhalers for Asthma and COPD - Jun 06, 2024
• Inhalers for Asthma and COPD - Feb 01, 2024
• Inhalers for Asthma/COPD - Dec 01, 2022

• Asthma and COPD maintenance medications - Oct 01, 2020
• Asthma and COPD Maintenance Medications - May 23, 2019
• Class Scan: Asthma and COPD - Jan 25, 2018
• Drugs to Treat Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Sep 29, 2016
• Asthma and COPD - Sep 24, 2015

• August 2023 - 2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on Revised Recommendations for Inhaler Products
• May 2017 - Updates in the Management of Chronic Obstructive Pulmonary Disease

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.